Biosimilars
Delivering high‑quality biologic alternatives that support patient access and affordability.
Through the Aisling brand, NorthStar is introducing affordable, high‑quality biosimilars that deliver additional value to its customers. Our biosimilars support supply predictability, sustainability, and operational simplicity, providing healthcare providers with a stable alternative in a market often disrupted by price volatility and supply challenges. Our biosimilars help practices reduce risk and stay focused on patient care.
Each product is developed and manufactured to meet the rigorous standards set by the U.S. Food and Drug Administration (FDA), ensuring safety, purity, and potency comparable to the reference product.
Why biosimilars matter
- Biosimilars help increase patient access to biologic therapies.
- They are developed to be highly similar to an FDA‑approved reference biologic.
- They support healthcare systems in managing rising therapy costs.
- Biosimilars undergo a thorough FDA evaluation across analytical, preclinical, and clinical data to confirm similarity.
Introducing Aisling Stimufend
Aisling Stimufend (pegfilgrastim‑fpgk) is our first biosimilar, offering a high‑quality treatment option with a focus on more stable supply, and operational simplicity.
